Perioperative medicine & outcomes
Intravenous Lidocaine for Gut Function Recovery in Colonic Surgery: A Randomized Clinical Trial
An erratum to this article was published (JAMA, 8 Apr 2025 ↗)
Authors' conclusion
Among patients undergoing elective minimally invasive colon resection, perioperative administration of 2% intravenous lidocaine did not improve return of gut function at 72 hours.
Study context
- Population
- Adults scheduled for elective minimally invasive colon resection for benign or malignant disease, 27 UK hospitals557 included
- Participants
- 590 adults
- Comparison
- 2% IV lidocaine vs saline placebo
- Lidocainen = 279
- Placebon = 278reference
- Primary endpoint
- Return of gut function (GI-3 composite: tolerating diet and passage of flatus or stool)
- Follow-up
- 72 hours after surgery
Methodological detailsplacebo-controlled, double-blind, multicentre (27 UK hospitals), Enrollment August 13, 2018, to April 11, 2023, with recruitment pause March 20, 2020, through July 6, 2020
- Placebo-controlled
- Double-blind
- Multicentre (27 UK hospitals)
- Enrollment August 13, 2018, to April 11, 2023, with recruitment pause March 20, 2020, through July 6, 2020
Primary result
As reported in the abstract
72 hours
Each group vs placeboAdjusted absolute difference (95% CI)
Lidocaine
−1.9%(−8.0% to 4.2%)
Each group vs placeboRelative risk (95% CI)
Lidocaine
0.97(0.88–1.07)
Secondary outcomes
11 secondary end points (incl. time to GI-3/GI-2 recovery, prolonged ileus, PONV score, opioid consumption, QoR-15, time to discharge criteria)
- No significant difference between groups in any of the 11 secondary end points
Original publication
Intravenous Lidocaine for Gut Function Recovery in Colonic Surgery: A Randomized Clinical Trial. JAMA. Published 7 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →